Eris Lifesciences Limited
Symboli: ERIS.NS
NSE
873.35
INRMarkkinahinta tänään
30.7423
P/E-suhde
1.6041
PEG-suhde
118.82B
MRK Cap
- 0.00%
DIV Tuotto
Eris Lifesciences Limited (ERIS-NS) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 5613.44 | 892.4 | 1772.4 | 522.7 | |||||||||||
balance-sheet.row.short-term-investments | 6124.75 | 332.2 | 1264.5 | 154 | |||||||||||
balance-sheet.row.net-receivables | 6515.97 | 2966.9 | 2260.9 | 2280.6 | |||||||||||
balance-sheet.row.inventory | 2705.24 | 1314.3 | 1179.1 | 944.7 | |||||||||||
balance-sheet.row.other-current-assets | 5222.75 | 2473.5 | 1060.8 | 922.5 | |||||||||||
balance-sheet.row.total-current-assets | 20057.4 | 7647.2 | 6273.3 | 4670.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 7998.42 | 3773.8 | 1918.6 | 778.8 | |||||||||||
balance-sheet.row.goodwill | 6636.98 | 3318.5 | 934.7 | 934.7 | |||||||||||
balance-sheet.row.intangible-assets | 37042.03 | 18806 | 6596 | 6840.8 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 43679.01 | 22124.5 | 7530.7 | 7775.5 | |||||||||||
balance-sheet.row.long-term-investments | 16.43 | 68.8 | 4208.4 | 2859.2 | |||||||||||
balance-sheet.row.tax-assets | 5690.48 | 2739.4 | 2431.3 | 2006.3 | |||||||||||
balance-sheet.row.other-non-current-assets | -2016.58 | 319.6 | 359 | 257.6 | |||||||||||
balance-sheet.row.total-non-current-assets | 55367.76 | 29026.1 | 16448.1 | 13677.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 75425.16 | 36673.3 | 22721.4 | 18347.8 | |||||||||||
balance-sheet.row.account-payables | 2752.94 | 1247.7 | 1177.7 | 1026.2 | |||||||||||
balance-sheet.row.short-term-debt | 3903.21 | 1932.9 | 40.1 | 23.3 | |||||||||||
balance-sheet.row.tax-payables | 176.96 | 39 | 70 | 77.5 | |||||||||||
balance-sheet.row.long-term-debt-total | 13158.94 | 6834.2 | 803.9 | 44.5 | |||||||||||
Deferred Revenue Non Current | 623.49 | 87.4 | 56.9 | 61.1 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 5109.42 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 438.6 | 217.2 | 152.4 | 132.5 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 19538.95 | 10034.2 | 1642.9 | 914.3 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 903 | 466.9 | 394 | 67.7 | |||||||||||
balance-sheet.row.total-liab | 28942.66 | 14466.5 | 3639.4 | 2583.6 | |||||||||||
balance-sheet.row.preferred-stock | 21930.12 | 21930.1 | 19062.4 | 15722.7 | |||||||||||
balance-sheet.row.common-stock | 272.01 | 136 | 135.9 | 135.8 | |||||||||||
balance-sheet.row.retained-earnings | 21559.3 | 21559.3 | 18736.5 | 15503.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 70084.98 | 29.8 | 20.7 | 41.5 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | -21288.35 | -21695.3 | -18872.5 | -15638.9 | |||||||||||
balance-sheet.row.total-stockholders-equity | 92558.06 | 21959.9 | 19083.1 | 15764.2 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 121907.66 | 36673.3 | 22721.4 | 18347.8 | |||||||||||
balance-sheet.row.minority-interest | 406.94 | 246.9 | -1.1 | 0 | |||||||||||
balance-sheet.row.total-equity | 92965 | 22206.8 | 19082 | 15764.2 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 121907.66 | - | - | - | |||||||||||
Total Investments | 5883.66 | 143.5 | 4208.4 | 2436.4 | |||||||||||
balance-sheet.row.total-debt | 17062.15 | 8767.1 | 844.1 | 67.8 | |||||||||||
balance-sheet.row.net-debt | 17573.46 | 8206.9 | 336.1 | -300.9 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 3864.39 | 4046.4 | 4422 | 3945 | |||||||||||
cash-flows.row.depreciation-and-amortization | 1638.34 | 1170.9 | 647 | 429.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | -809.7 | -976.6 | -670.9 | |||||||||||
cash-flows.row.stock-based-compensation | 31.21 | 31.2 | 13.6 | 11.2 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | -1755.4 | -299 | 53.3 | |||||||||||
cash-flows.row.account-receivables | 0 | -1171.4 | -204.8 | 159 | |||||||||||
cash-flows.row.inventory | 0 | 47.4 | -234.4 | -249.9 | |||||||||||
cash-flows.row.account-payables | 0 | -105 | 151.6 | 25.7 | |||||||||||
cash-flows.row.other-working-capital | 0 | -526.5 | -11.3 | 118.6 | |||||||||||
cash-flows.row.other-non-cash-items | -3895.6 | 233.9 | -24.4 | -14.7 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 2605.29 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -8414.2 | -1210.3 | -257.6 | |||||||||||
cash-flows.row.acquisitions-net | 0 | -6554.9 | -103 | -2.8 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -300 | -2677.7 | -3733.9 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 5204.4 | 795.9 | 774.2 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 243.7 | -1 | -13.4 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -9821 | -3196.1 | -3233.6 | |||||||||||
cash-flows.row.debt-repayment | 0 | -3500 | -450 | -0.1 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 22.8 | 67.5 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 3477.2 | -450 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | -999.1 | -816.2 | -746.8 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 7879.4 | 1201.8 | -77.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 6880.3 | -447 | -824 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 74.9 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 2605.29 | 51.5 | 139.6 | -303.9 | |||||||||||
cash-flows.row.cash-at-end-of-period | 6306.92 | 560.2 | 508.7 | 369.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 3701.63 | 508.7 | 369.1 | 673.1 | |||||||||||
cash-flows.row.operating-cash-flow | 2605.29 | 2917.4 | 3782.6 | 3753.6 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -8414.2 | -1210.3 | -257.6 | |||||||||||
cash-flows.row.free-cash-flow | 2605.29 | -5496.8 | 2572.3 | 3496 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 18406.22 | 16618.2 | 13261.7 | 11926.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 3346.18 | 3523.5 | 2608.1 | 2418.7 | |||||||||||
income-statement-row.row.gross-profit | 15060.04 | 13094.7 | 10653.6 | 9507.8 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 61 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 1189.54 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 63.85 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 96.71 | 111.5 | 10.4 | 4.5 | |||||||||||
income-statement-row.row.operating-expenses | 10245.46 | 8898.1 | 6403 | 5620 | |||||||||||
income-statement-row.row.cost-and-expenses | 13591.64 | 12421.6 | 9011.1 | 8038.7 | |||||||||||
income-statement-row.row.interest-income | 402.19 | 23 | 61 | 22.9 | |||||||||||
income-statement-row.row.interest-expense | 606.36 | 261.7 | 41.5 | 18 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 63.85 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -596.47 | -170.2 | 176.9 | 68.9 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 96.71 | 111.5 | 10.4 | 4.5 | |||||||||||
income-statement-row.row.total-operating-expenses | -596.47 | -170.2 | 176.9 | 68.9 | |||||||||||
income-statement-row.row.interest-expense | 606.36 | 261.7 | 41.5 | 18 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 1638.34 | 1170.9 | 647 | 429.9 | |||||||||||
income-statement-row.row.ebitda-caps | 6549.63 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 4901.4 | 4216.6 | 4245 | 3876.1 | |||||||||||
income-statement-row.row.income-before-tax | 4304.93 | 4046.4 | 4422 | 3945 | |||||||||||
income-statement-row.row.income-tax-expense | 515.94 | 304.8 | 364.1 | 393.6 | |||||||||||
income-statement-row.row.net-income | 3864.39 | 3821.6 | 4061.1 | 3551.3 |
Usein kysytty kysymys
Mikä on Eris Lifesciences Limited (ERIS.NS) taseen loppusumma?
Eris Lifesciences Limited (ERIS.NS) kokonaisvarat ovat 36673280000.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on 9840010000.000.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.818.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on 19.153.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on 0.210.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on 0.266.
Mikä on Eris Lifesciences Limited (ERIS.NS) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on 3821580000.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 8767110000.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 8898080000.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat -1906240000.000.